Inferra AI / Company / CSTL

Castle Biosciences Inc.

CSTL · Health Care

Last earnings Jul 30, 2026

Key results

Operational Highlights revenuequarter

$86.2 million

Second Quarter Ended June 30, 2025, Financial and Operational Highlights Revenues were $86.2 million, compared to $87.0 million in the second quarter of 2024.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Gross marginquarter

77%

Gross margin was 77%, and Adjusted Gross Margin was 80%, compared to 81% and 83%, respectively, for the same periods in 2024.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Adjusted gross marginquarter

80%

Gross margin was 77%, and Adjusted Gross Margin was 80%, compared to 81% and 83%, respectively, for the same periods in 2024.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Six Months Ended June 30, 2025, Financial and Operational Highlights Revenues were $174.2 million, a 9% increase c ompared to $160.0 million during the same period in 2024.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Gross margin for the six months ended June 30, 2025, was 63%, and Adjusted Gross Margin was 81%.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Adjusted Gross Margin was 80%, compared to 81% and 83% respectively for the same periods in 2024 5 Net cash provided by operations in Q225 was $20.8 million, compared to $24.0 million net cash provided by operations in Q224 6 Q225 total test reports for our core revenue drivers (DecisionDx&reg

SEC original ↗Castle Biosciences Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025

AI analysis

Q2 2025 · reported Aug 4, 2025

Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held

Gross margin · Q2 2025

77%

-4.0 pts vs year ago computed from stated figures

EX-99 · Aug 4, 2025

Operational Highlights revenue · Q2 2025

$86.2M

-0.9% vs year ago computed from stated figures

EX-99 · Aug 4, 2025

Adjusted gross margin · Q2 2025

80%

-1.0 pts vs year ago computed from stated figures

EX-99 · Aug 4, 2025

The quarter in charts

GAAP gross margin

Percent of revenue, as stated

EX-99 · Aug 4, 2025 Margin values as stated in the release.

Headline figures

Metric	Q2 2025	Prior qtr	Year ago
Operational Highlights revenue	$86.2 million	—	$87.0 million
Gross margin	77%	—	81%
Adjusted gross margin	80%	—	81%

EX-99 · Aug 4, 2025

Guidance · company-stated

Direction: Raised

Revenue$86 million

“htm EX-99.1 Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4 30 p.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Gross margin77%

Adjusted gross margin80%

Capital allocation

Marketable Investment Securities Our marketable investment securities are comprised of debt and equity securities.

All debt securities are recognized in accordance with Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) Topic 320, Investments-Debt Securities ( ASC 320 ).

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Delivered 26,574 total test reports in the second quarter of 2025, an increase of 6% compared to 25,102 in the same period of 2024

Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4 30 p.”

Revenue — Raised (“increased”)
“htm EX-99.1 Document Exhibit 99.1 Castle Biosciences Reports Second Quarter 2025 Results Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx -Melanoma, TissueCypher ) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million Conference call and webcast today at 4 30 p.”

Revenue — Raised (“raising”)
“2025 Outlook Castle Biosciences is raising its guidance for anticipated total revenue in 2025.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Marketable Investment Securities Our marketable investment securities are comprised of debt and equity securities.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

All debt securities are recognized in accordance with Financial Accounting Standards Board ( FASB ) Accounting Standards Codification ( ASC ) Topic 320, Investments-Debt Securities ( ASC 320 ).

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Management determines the appropriate classification of debt securities at the time of purchase and re-evaluates such determination at each balance sheet date.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Debt securities that are classified as available-for-sale ( AFS ) are recorded at fair value in accordance with ASC 320.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Debt securities that are classified as held-to-maturity ( HTM ) are reported at amortized cost in accordance with ASC 320.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Realized gains and losses on AFS and HTM debt securities, if any, are calculated at the individual security level and included in interest income in the condensed consolidated statements of operations.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Strategy & priorities

In alignment with our capital allocation priorities and M A strategy, we closed the Previse tuck-in acquisition and announced an exciting collaboration and license agreement with SciBase, both of which we believe will support our mid- to long-term value creation goals.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

At the same time, we remain deeply focused on execution across our current test portfolio, which we believe positions us well for continued near-term success.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Our ability to invest in the future while advancing our core franchises reflects the strength of our growth initiatives and commitment to delivering sustainable value to our stakeholders.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Pipeline Initiatives The Company announced that it entered into a collaboration and license agreement with SciBase Holding AB ( SciBase ) utilizing SciBase s Electrical Impedance Spectroscopy technology, which includes both desktop and point-of-care instruments.

SEC original ↗Castle Biosciences Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025

Real world histologic grading TissueCypher risk class ©2025 Castle Biosciences 19 Advancing penetration of our tests with clinicians and payers Expert Consensus & Guidelines1 Reimbursement Strategy Castle Commercial Playbook PENETRATE 1.

SEC original ↗Castle Biosciences Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025

Risks & headwinds

These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: our estimates and assumptions underlying our estimated U.

SEC original ↗Castle Biosciences Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025

Legal Proceedings 48 Item 1A.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

The amounts are estimated using historical average collection rates by test type and payor category taking into consideration the range of possible outcomes, the predictive value of our past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of our influence, such as the judgment and actions of third parties.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Such variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

, judgment or actions of third parties) and the uncertainty of the amount to be received is not expected to be resolved for a long period of time.

SEC original ↗Castle Biosciences Inc. — 10-Q Quarterly report10-QJul 30, 2026

Documents

Earnings deck slides

0 decks with slide view

Castle Biosciences Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors